Tags

Type your tag names separated by a space and hit enter

Photodynamic therapy for polypoidal choroidal vasculopathy.
Prog Retin Eye Res. 2013 Nov; 37:182-99.PR

Abstract

The first effective therapy for exudative macular degeneration (AMD) was Photodynamic Therapy (PDT). Diagnosis of the disease was to a large extent by fluorescein angiography (FA). Distinguishing between the leaky choroidal neovessels (CNV) associated with exudative AMD, and the polypoidal structures associated with Polypoidal Choroidal Vasculopathy (PCV) is not always easy using FA alone. The switch to Indocyanine Green angiography helped to pinpoint PCV, and thus to study the efficacy of photodynamic therapy of this particular form of retinal disease, which is more frequently encountered among pigmented individuals. The results appear to be quite promising, and in the year following treatment only a small fraction of the patients had to be retreated. Alternatively, treating PCV with repeated intravitreal VEGF blocking agents was not as successful as it was in the treatment of wet AMD. However, combining PDT-induced angio-occlusion of the polypoidal lesions with anti-vascular endothelial growth factor therapy was shown to be quite effective, and the combination of PDT with an anti-angiogenic agent as well as a steroid, in a triple therapy, was recently also shown to be a quite promising option. In the present article we review the data on PDT of PCV, including combination therapies and alternative treatments. We also report on similarities and differences between AMD and PCV.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Nowak-Sliwinska P
Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland; University Hospital (CHUV), Lausanne, Switzerland. Electronic address: Patrycja.Nowak-Sliwinska@epfl.ch.
van den Bergh H
No affiliation info available
Sickenberg M
No affiliation info available
Koh AH
No affiliation info available

MeSH

Angiogenesis InhibitorsChoroid DiseasesCombined Modality TherapyDrug Therapy, CombinationHumansLow-Level Light TherapyMacular DegenerationPhotochemotherapyPhotosensitizing Agents

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24140257

Citation

Nowak-Sliwinska, Patrycja, et al. "Photodynamic Therapy for Polypoidal Choroidal Vasculopathy." Progress in Retinal and Eye Research, vol. 37, 2013, pp. 182-99.
Nowak-Sliwinska P, van den Bergh H, Sickenberg M, et al. Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res. 2013;37:182-99.
Nowak-Sliwinska, P., van den Bergh, H., Sickenberg, M., & Koh, A. H. (2013). Photodynamic therapy for polypoidal choroidal vasculopathy. Progress in Retinal and Eye Research, 37, 182-99. https://doi.org/10.1016/j.preteyeres.2013.09.003
Nowak-Sliwinska P, et al. Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Prog Retin Eye Res. 2013;37:182-99. PubMed PMID: 24140257.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Photodynamic therapy for polypoidal choroidal vasculopathy. AU - Nowak-Sliwinska,Patrycja, AU - van den Bergh,Hubert, AU - Sickenberg,Michel, AU - Koh,Adrian H C, Y1 - 2013/10/15/ PY - 2013/07/29/received PY - 2013/09/23/revised PY - 2013/09/27/accepted PY - 2013/10/22/entrez PY - 2013/10/22/pubmed PY - 2014/5/6/medline KW - 11-cis-RAL KW - 11-cis-REH KW - 11-cis-retinal KW - 11-cis-retinyl ester hydrolase KW - A2E KW - A2PE KW - ABCA4 KW - AMD KW - AREDS KW - ATP-binding cassette transporter 4 KW - Age-related macular degeneration KW - Anti-Angiogenesis KW - BCVA KW - BPDMA KW - BVN KW - CFH KW - CNV KW - CRALBP KW - Choroidal neovascularization KW - ELN KW - ETDRS KW - Early Treatment Diabetic Retinopathy Study KW - FV KW - HTRA1 KW - ICGA KW - IVB KW - IVTA KW - LRAT KW - MII KW - N-ret-PE KW - N-retinylidine-phosphatidyl ethanolamine KW - OCT KW - OS KW - Optical coherence tomography KW - PCV KW - PDGF KW - PE KW - PED KW - PEGF KW - PTPC KW - Polypoidal choroidal vasculopathy KW - RDH KW - ROS KW - RPED KW - SMA KW - SNP KW - V(®)-PDT KW - VDA KW - VEGF-A KW - Visudyne(®)-photodynamic therapy KW - age-related eye disease study KW - age-related macular degeneration KW - all-trans-RAL KW - all-trans-RE KW - all-trans-retinal KW - all-trans-retinal ester KW - benzoporphyrin derivative monoacid ring A KW - best-corrected visual acuity KW - branching vascular network KW - cellular retinaldehyde-binding protein KW - choroidal neovascularization KW - complement factor H KW - di-retinoid-pyridinium-ethanolamine KW - elastin gene KW - epithelium-derived growth factor KW - feeder vessels KW - high temperature required factor A1 KW - indocyanine green angiography KW - intravitreal ranibizumab KW - intravitreal triamcinolone acetonide KW - lecithin:retinol acyltransferase KW - mTOR KW - mammalian target of rapamycin KW - metarhodopsin II KW - optical coherence tomography KW - outer segment KW - permeability transition pore complex KW - phosphatidylethanolamine KW - phosphatidylpyridinium-bisretinoid KW - pigment epithelial detachment KW - platelet-derived growth factor KW - polypoidal choroidal vasculopathy KW - reactive oxygen species KW - retinal pigmented epithelium detachment KW - retinol dehydrogenase enzymes KW - single nucleotide polymorphism KW - smooth muscle actin KW - vWf KW - vascular disrupting agent KW - vascular endothelial growth factor A KW - von Willebrand factor SP - 182 EP - 99 JF - Progress in retinal and eye research JO - Prog Retin Eye Res VL - 37 N2 - The first effective therapy for exudative macular degeneration (AMD) was Photodynamic Therapy (PDT). Diagnosis of the disease was to a large extent by fluorescein angiography (FA). Distinguishing between the leaky choroidal neovessels (CNV) associated with exudative AMD, and the polypoidal structures associated with Polypoidal Choroidal Vasculopathy (PCV) is not always easy using FA alone. The switch to Indocyanine Green angiography helped to pinpoint PCV, and thus to study the efficacy of photodynamic therapy of this particular form of retinal disease, which is more frequently encountered among pigmented individuals. The results appear to be quite promising, and in the year following treatment only a small fraction of the patients had to be retreated. Alternatively, treating PCV with repeated intravitreal VEGF blocking agents was not as successful as it was in the treatment of wet AMD. However, combining PDT-induced angio-occlusion of the polypoidal lesions with anti-vascular endothelial growth factor therapy was shown to be quite effective, and the combination of PDT with an anti-angiogenic agent as well as a steroid, in a triple therapy, was recently also shown to be a quite promising option. In the present article we review the data on PDT of PCV, including combination therapies and alternative treatments. We also report on similarities and differences between AMD and PCV. SN - 1873-1635 UR - https://www.unboundmedicine.com/medline/citation/24140257/Photodynamic_therapy_for_polypoidal_choroidal_vasculopathy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1350-9462(13)00059-1 DB - PRIME DP - Unbound Medicine ER -